Substituted piperazines as dopamine D3/D2 receptor modulators
US12168007B1 · kind B1 · utility
0Cited by
0References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 10, 2024 |
| Grant date | Dec 17, 2024 |
| Priority date | — |
| Expiry date | Jan 10, 2044 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides for compounds of Formula (I): wherein R1 has any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions including schizophrenia. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.